Fundraising Fox
/People
Sign in

Maha Katabi

Investor

General Partner at Sofinnova Ventures · Board director at Marea Therapeutics, Inc. · Board director at Veratx · Board director at Star Therapeutics

Montreal

Writes $100K – $5M checks · typically $1.5M

Find your path to Maha

249 people in our graph share verified history with Maha — schools, employers, funds. One of them is your warm intro.

Gary PatouunlockedMaha: together at Star Therapeutics (2023–2026)
Maha: together at Star Therapeutics
×3Maha: together at Ventures West
Maha: together at Amplyx Pharmaceuticals

About

Maha Katabi is a PhD in Pharmacology and CFA who built crossover public/private biotech investing platforms, focuses on clinical‑stage single‑asset radiopharmaceutical and targeted oncology companies, and chairs Exactis Innovation.

Contact· self-published, not guessed

Invests in

BiotechHealthtechMedical Devices

Board director at Marea Therapeutics, Inc.

Intro paths

→

In turn, Maha can intro founders to Marea Therapeutics, Inc.'s investors below.

Marea Therapeutics, Inc.'s investors · 3

Sofinnova VenturesMenlo Park · $100K – $15M checks · since 2024Third Rock VenturesBoston · $100K – $5M checks · since 2024venBio PartnersSan Francisco · since 2024

Board director at Veratx

Intro paths

→

In turn, Maha can intro founders to Veratx's investors below.

Veratx's investors · 5

AbingworthLondon · $15M – $30M checks · since 2020Kleiner PerkinsMenlo Park · $500K – $15M checks · since 2020Longitude CapitalMenlo Park · $10M – $30M checks · since 2020Sofinnova Venture PartnersMenlo Park · since 2020Sofinnova VenturesMenlo Park · $100K – $15M checks · since 2021

Co-founders at Veratx

MF
Marshall FordyceExecutive Officer, Director

Board director at Star Therapeutics

Intro paths

→

In turn, Maha can intro founders to Star Therapeutics's investors below.

Star Therapeutics's investors · 17

Agent CapitalWaltham · since 2025Blue Owl CapitalNew York · since 2025Catalio Capital ManagementNew York · since 2025Cowen Healthcare InvestmentsNew York · since 2025Frazier Life SciencesPalo Alto · since 2025Janus Henderson InvestorsLondon · since 2025Kleiner PerkinsMenlo Park · $500K – $15M checks · since 2022New Leaf Venture PartnersNew York · since 2025NYBC VenturesNew York · since 2025OrbiMedNew York · $1M – $75M checks · since 2025Qatar Investment AuthorityDoha · since 2025RA CapitalBoston · since 2025REDMILESan Francisco · since 2025Sanofi VenturesCambridge · $5M checks · since 2025Sofinnova VenturesMenlo Park · $100K – $15M checks · since 2025Viking Global InvestorsStamford · since 2025Westlake Village BioPartnersLos Angeles · $100K – $5M checks · since 2025

Co-founders at Star Therapeutics

ARAdam Rosenthal
Adam RosenthalFounder & CEO
NS
Nancy StaglianoDirector

Experience

  1. Sofinnova InvestmentsGeneral Partnercurrent2020 — present
  2. Sofinnova InvestmentsPartner2019 — 2020
  3. Star TherapeuticsBoard Membercurrent2023 — presentSouth San Francisco, California, United States
  4. Quanta TherapeuticsBoard Membercurrent2021 — presentSan Francisco Bay Area
  5. Marea TherapeuticsBoard Membercurrent2024 — present
  6. ARTBIOBoard Membercurrent2025 — present
  7. Coultreon BiopharmaBoard Membercurrent2026 — present
  8. Vera Therapeutics, Inc.Board Member2020 — 2026Redwood City, California, United States
  9. Exactis InnovationChair of the Board of Directors2019 — 2025
  10. Aiolos BioBoard Member2023 — 2024
  11. RayzeBioBoard Member2022 — 2024San Diego, California, United States
  12. Aerovate Therapeutics, Inc.Board Member2020 — 2024Boston, Massachusetts, United States
  13. GYROSCOPE TxBoard Member2021 — 2022London Area, United Kingdom
  14. NorthSea TherapeuticsBoard Member2019 — 2022Amsterdam, North Holland, Netherlands
  15. Amplyx Pharmaceuticals, IncBoard Member2020 — 2021San Diego, California, United States
  16. Oxalis CapitalManaging Partner2018 — 2019Greater Montreal Metropolitan Area
  17. Sectoral Asset ManagementPartner, Private Equity2008 — 2018
  18. Apellis PharmaceuticalsBoard Member2017Massachusetts, United States
  19. Ventures WestVice-President2004 — 2008
  20. T2C2 CapitalAssociate1999 — 2002

Skills & more

  • Chartered Financial Analyst (CFA) — CFA Institute
  • Chartered Financial Analyst Charterholder — CFA Institute

From Maha's professional profile.

Deals · 4

Marea Therapeutics, Inc.Board seat

via Sofinnova Ventures · filed Jun 2024 · $160.4M raise

Gyroscope Therapeutics LtdBoard seat

via Sofinnova Ventures · filed Apr 2021 · $148M raise

Aerovate Therapeutics, Inc.Board seat

via Sofinnova Ventures · filed Aug 2020 · $75.8M raise

Effector TherapeuticsBoard seat

via Sofinnova Ventures · filed Feb 2016 · $56M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

AerovateAiolosAmplyxApellis PharmaceuticalsARTBIOCoultreonExpedition TherapeuticsGyroscopeMarea TherapeuticsNorthsea TherapeuticsQuanta TherapeuticsQuanta TherapeuticsRayze BioRayze BioStar TherapeuticsStar TherapeuticsVera Therapeutics (VERA)Veratx

Investor

Aerovate TherapeuticsApellis PharmaceuticalsApellis Pharmaceuticals (APLS)ARTBIOAscendis Pharma (ASND)CoultreonF2GGyroscopetxQuanta TherapeuticsRayze BioStar TherapeuticsTrius Therapeutics (TSRX-acquired by Cubist)Vera Therapeutics

Sources: the firm's website · SEC Form D filings · curated public sources.

Colleagues at Sofinnova Ventures

Alex Chan
Controller, Private Equity at Sofinnova Ventures
Alex Dulnev
IT Manager at Sofinnova Ventures
Amanda Phillips
Executive Assistant at Sofinnova Ventures
Anastasia Voevodin
Analyst, Public Equity at Sofinnova Ventures
Aneal Tenjarla
Partner, Associate Portfolio Manager, Public Equity at Sofinnova Ventures
Calvin Sternick
Analyst, Public Equity at Sofinnova Ventures
Chris Carpenter
Executive Partner, Private Equity at Sofinnova Ventures
Daniel Ni, MD, PhD
Analyst, Public Equity at Sofinnova Ventures

Network1

Carl Gordon
Managing Partner at OrbiMed

Investors connected to Maha in public investor directories — a warm-intro map.

Frequently asked questions

Who is Maha Katabi?
Maha Katabi is a PhD in Pharmacology and CFA who built crossover public/private biotech investing platforms, focuses on clinical‑stage single‑asset radiopharmaceutical and targeted oncology companies, and chairs Exactis Innovation.
Where does Maha Katabi work?
Maha Katabi is General Partner at Sofinnova Ventures and Board director at Marea Therapeutics, Inc. and Board director at Veratx and Board director at Star Therapeutics.
What does Maha Katabi invest in?
Maha Katabi invests in Biotech, Healthtech, Medical Devices.
What check size does Maha Katabi write?
Maha Katabi typically writes checks of $100K – $5M.
What boards does Maha Katabi sit on?
Maha Katabi holds tracked board seats at Aerovate, Aerovate Therapeutics, Inc., Aiolos, Amplyx, Apellis Pharmaceuticals, ARTBIO, Coultreon, Effector Therapeutics, Expedition Therapeutics, Gyroscope.
What companies has Maha Katabi invested in?
Investments tracked here include Aerovate Therapeutics, Apellis Pharmaceuticals, Apellis Pharmaceuticals (APLS), ARTBIO, Ascendis Pharma (ASND), Coultreon, Effector Therapeutics, F2G, Gyroscopetx, Marea Therapeutics, Inc., Quanta Therapeutics, Rayze Bio, and 3 more.
Where did Maha Katabi go to school?
Maha Katabi studied at McGill University (Doctor of Philosophy (PhD), Pharmacology and Therapeutics).

Same school

Shared employers